Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women
Krauss-Etschmann S, Hartl D, Rzehak P, Heinrich J, Shadid R, Del Carmen Ramírez-Tortosa M, Campoy C, Pardillo S, Schendel DJ, Decsi T, Demmelmair H, Koletzko BV, Nutraceuticals for Healthier Life Study Group
The Journal of allergy and clinical immunology · 106 citas
Etiquetas de revisión
Financiación no declaradaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2007-12-04 · J Allergy Clin Immunol · vol. 121 · número 2 · págs. 464–470.e6
- Editorial
- Elsevier BV
- Citado
- 160 citas · más que el 98% de estudios similares · 10.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Asthma and respiratory diseases · Food Allergy and Anaphylaxis Research
- Palabras clave
- fish oil supplementation, pregnancy, umbilical cord blood, Th1/Th2 balance, IL-4, IL-13, CCR4, TGF-beta, interferon-gamma, interleukin-1, docosahexaenoic acid, eicosapentaenoic acid, maternal immune response, allergy prevention, prenatal nutrition, maternal-fetal immune transfer, methyltetrahydrofolate
- MeSH
- lymphocyte subsets, fetal blood, humans, docosahexaenoic acids, fish oils, transforming growth factor beta, rna, messenger, inflammation mediators, interleukin-4, interleukin-13, cytokines, delivery, obstetric, double-blind method, pregnancy, dietary supplements, adult, infant, newborn, female, male, receptors, ccr4
12 autores
- Susanne Krauss‐Etschmann🇩🇪 · autor de correspondenciaHelmholtz Munich; Ludwig-Maximilians-Universität München
- Dominik Hartl🇩🇪Helmholtz Munich; Ludwig-Maximilians-Universität München
- Peter Rzehak🇩🇪Helmholtz Munich; Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie; Ludwig-Maximilians-Universität München
- Joachim Heinrich🇩🇪Helmholtz Munich
- Rania Shadid🇩🇪Helmholtz Munich; Ludwig-Maximilians-Universität München
- María del Carmen Ramirez-Tortosa🇪🇸Universidad de Granada
- Cristina Campoy🇪🇸Universidad de Granada
- S. Pardillo🇪🇸Universidad de Granada
- Dolores J. Schendel🇩🇪Helmholtz Munich
- Támas Décsi🇭🇺University of Pecs
- Hans Demmelmair🇩🇪Ludwig-Maximilians-Universität München
- Berthold Viktor Koletzko🇩🇪Ludwig-Maximilians-Universität München
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Altered intakes of n-3 and n-6 polyunsaturated fatty acids were suggested to modulate allergic disease, but intervention trials yielded inconclusive results. Because allergies are primed in early infancy and in utero, the fetus might be more accessible to nutritional intervention strategies.
Objective
We sought to investigate how supplementation of pregnant women with a fish oil (FO) preparation modulates allergy-related immune parameters in mothers and offspring.
Methods
We performed a multicenter, randomized, double-blind, placebo-controlled trial. Three hundred eleven pregnant women received daily either FO with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mug of methyl-tetra-hydrofolic acid, both, or placebo from the 22nd gestational week. T(H)1/T(H)2-related molecules were quantified in 197 maternal and 195 cord blood samples by using real-time RT-PCR. Data are given as geometric means [95% CIs].
Results
FO supplementation was associated with increased TGF-beta mRNA in maternal (0.85 [0.8-0.89]; placebo: 0.68 [0.64-0.72]) and cord blood (0.85 [0.81-0.9]; placebo: 0.75 [0.71-0.79]). IL-1 (0.69 [0.66-0.73]; placebo: 0.83 [0.79-0.88]) and IFN-gamma (0.54 [0.51-0.57]; placebo: 0.65 [0.61-0.69]) were decreased in mothers only (P < .001). Cord blood mRNA levels of IL-4 (0.54 [0.52-0.57]; placebo: 0.64 [0.61-0.68]), IL-13 (0.61 [0.58-0.65]; placebo: 0.85 [0.80-0.89]), CCR4 (0.70 [0.67-0.73]; placebo: 0.88 [0.84-0.92]; all P < .001), and natural killer (P < .001) and CCR3+CD8+ T cells (P < .04) were decreased in the FO group.
Conclusion
Supplementation with FO during pregnancy is associated with decreased mRNA levels of T(H)2-related molecules in the fetus and decreased maternal inflammatory cytokines. We speculate that both effects are mediated by TGF-beta.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.